Testosterone, DHT, Body Hair, Beard Growth, and Male Pattern Baldness: The Androgen Paradox

The relationship between androgens (testosterone and its derivatives) and hair is paradoxical: the same hormonal environment that drives beard growth and body hair development also causes the progressive miniaturization of scalp hair follicles in male pattern baldness. The hormone is the same; the follicle response is opposite depending on location.

Understanding this resolves the apparent contradiction between "high testosterone = more beard" and "high testosterone = faster hair loss."

The DHT Mechanism

Testosterone is converted to dihydrotestosterone (DHT) by the enzyme 5-alpha reductase, which is expressed in hair follicles. DHT has approximately 3–5x greater binding affinity for the androgen receptor than testosterone and is more potent in driving androgen-sensitive responses.

Body hair and beard follicles: Androgen receptors in these follicles respond to DHT by extending the anagen (growth) phase and increasing follicle size. DHT promotes hair growth in these locations.

Scalp follicles (in genetically susceptible men): Scalp follicles in those carrying the genetics for androgenetic alopecia respond to DHT in the opposite direction — progressive miniaturization of the follicle. The anagen phase shortens, the telogen (resting/shedding) phase extends, and the follicle progressively produces finer, shorter hairs until it becomes non-functional.

The genetic susceptibility: the androgen receptor gene on the X chromosome has variants associated with differential sensitivity to DHT. This is why male pattern baldness is partially inherited from the maternal grandfather (carrier of the maternal X chromosome) — a popular but oversimplified observation; multiple genes contribute.

> 📌 Ellis et al. (1998) confirmed that the density of androgen receptors in hair follicles differs between balding and non-balding scalp areas in the same individuals — with balding follicles showing significantly higher androgen receptor density, explaining the location-specific response to the same androgen environment. [1]

5-Alpha Reductase Inhibitors

This mechanism is the basis for the pharmaceutical treatment of male pattern baldness:

Finasteride (1mg, Propecia): Inhibits 5-alpha reductase type II, reducing DHT concentration in the scalp by approximately 60–70%. Approximately 60–70% of men taking finasteride show no further hair loss; a subset show regrowth. Side effects in approximately 2–3%: sexual dysfunction (libido changes, erectile dysfunction); typically reversible on cessation. The "post-finasteride syndrome" (persistent sexual side effects despite cessation) is reported but prevalence is debated.

Minoxidil: Different mechanism — vasodilation of scalp blood vessels, extended anagen phase through unknown mechanisms. Effective in approximately 60% of users; requires continued use to maintain effect.

Does Testosterone Level Predict Baldness?

No — reliably. Baldness is a function of DHT sensitivity at the follicle level, which is primarily determined by genetics (androgen receptor density and type). Men with relatively lower testosterone can develop severe baldness; men with high testosterone can have full hair. The determinant is the follicle's response to whatever DHT is present, not the total circulating androgen level.

---

Key Terms

• DHT (Dihydrotestosterone) — the potent androgen derivative of testosterone produced by 5-alpha reductase; 3–5x greater androgen receptor binding affinity than testosterone; promotes beard and body hair growth while causing scalp follicle miniaturization in genetically susceptible individuals
• Androgenetic alopecia (AGA) — the genetic form of male (and female) pattern hair loss; driven by DHT sensitivity in scalp follicles; the most common form of hair loss; treated with 5-alpha reductase inhibitors and minoxidil
• Follicle miniaturization — the progressive reduction in hair follicle size in androgenetic alopecia; anagen phase shortens, follicle diameter decreases, producing progressively finer and shorter hairs until the follicle becomes non-functional
• 5-alpha reductase — the enzyme that converts testosterone to DHT; expressed in follicles, prostate, and liver; type II isoform inhibited by finasteride; the pharmacological target of AGA treatment because its inhibition reduces DHT without reducing testosterone

---

Scientific Sources

• 1. Ellis, J.A., Sinclair, R., & Harrap, S.B. (2002). Androgenetic alopecia: Pathogenesis and potential for therapy. Expert Reviews in Molecular Medicine, 4(22), 1–11. PubMed